Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference
BEDMINSTER, N.J., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the...
Vaccine
TOMI Environmental Receives Order From National Institutes of Health (NIH); TOMI Products Now Deployed in Over 20 NIH Facilities Across 11 Divisions
FREDERICK, Md., Oct. 20, 2022 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in...
Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc....
Sunshine Biopharma Announces the Acquisition of Nora Pharma, Adding $10.7 Million in Revenue
MONTREAL, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company focused on the research, development...
Telesis Bio and Cellibre Announce Collaboration to Optimize Development of Future BioXp® DBC instrument
Agreement will allow researchers to streamline development of on-demand and automated production of CRISPR-Cas9 guide RNASAN DIEGO, Oct. 19, 2022...
Maravai LifeSciences Temporarily Reinstates Carl Hull as CEO Amidst Pending Noncompetition Litigation
Maravai LifeSciences and Recently-Appointed CEO Trey Martin Vigorously Defending Against SuitSAN DIEGO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Executive...
Providence Announces Positive Top-Line Data from Phase 2 Primary Immunization Trial of its mRNA Vaccine Candidate PTX-COVID19-B in Adults
PTX-COVID19-B was well tolerated with no safety signalsNon-inferior neutralizing antibody titer levels versus comparator vaccine, Comirnaty®Providence will initiate a Phase...
PDS Biotech to Present at the LD Micro Main Event XV
FLORHAM PARK, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a...
Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022
Highlighting Ocugen research and innovative technologies Featuring thought leaders in gene therapy and vaccines MALVERN, Pa., Oct. 19, 2022 (GLOBE...
Matinas BioPharma Announces Infectious Diseases Society of America (IDSA) has Selected the EnACT Phase 2 Trial Abstract of MAT2203 as its Outstanding Abstract and IDSA Awardee For IDWeek 2022
BEDMINSTER, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused...
Tonix Pharmaceuticals to Present at the 2022 ThinkEquity Conference
CHATHAM, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today...
Gritstone to Host Data Update on CORAL and Discuss the Application of Self-amplifying mRNA (samRNA) in Infectious Diseases
-- Data to be presented from CORAL-BOOST and CORAL-CEPI trials evaluating Gritstone’s samRNA vaccine candidates against SARS-CoV-2 -- EMERYVILLE, Calif.,...
SteraMist to be Used in a Global Influenza Vaccine Facility in Australia
Company Continues To See Strong Bookings and A Robust Pipeline For Its Custom Engineered Systems in The Life Science SectorFREDERICK,...
Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A
– First clinical trial evaluating the role of a monoclonal antibody in preventing seasonal flu – – Announcement follows recent...
Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA
Aligos’ pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2023SOUTH SAN FRANCISCO, Calif., Oct. 18,...
Sorrento Successfully Completes Phase 1 Study and Is Proceeding to Implement Global Registrational Trials with STI-1558, an Oral Mpro Inhibitor as a Standalone Oral Treatment and Prevention of COVID-19 without the Need for a Ritonavir Booster
Phase 1 Study (with 58 healthy volunteers) of STI-1558 was completed in Australia with 300 mg, 600 mg, 1,200 mg...
Bavarian Nordic Enters Agreement with Switzerland on the Supply of Smallpox and Monkeypox Vaccine
Switzerland has ordered 100,000 doses of smallpox and monkeypox vaccine with deliveries starting imminentlyBavarian Nordic will seek regulatory approval of...
Ramsay Sante : Annual results at the end of June 2022
PRESS RELEASE Paris, October 13th, 2022 Annual results at end June 2022 The solid performance of the Nordic countries has...
Altamira Therapeutics to Participate at RNA Leaders USA Congress
HAMILTON, BERMUDA , Oct. 13, 2022 (GLOBE NEWSWIRE) -- Event will be held on October 18-19, 2022 in Boston, MASamuel...
GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial
Data show overall vaccine efficacy of 82.6% against RSV-lower respiratory tract disease (LRTD) in adults aged 60 years and above,...